| Funding Opportunity ID: |
296366 |
| Opportunity Number: |
PAR-17-457 |
| Opportunity Title: |
NINDS CREATE Bio Optimization Track for Biologics (U44) |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Cooperative Agreement |
| Category of Funding Activity: |
Health |
| Category Explanation: |
|
| CFDA Number(s): |
93.853 |
| Eligible Applicants: |
Small businesses |
| Additional Information on Eligibility: |
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
| Agency Code: |
HHS-NIH11 |
| Agency Name: |
Department of Health and Human Services
National Institutes of Health |
| Posted Date: |
Aug 11, 2017 |
| Close Date: |
Sep 07, 2020 |
| Last Updated Date: |
Aug 11, 2017 |
| Award Ceiling: |
|
| Award Floor: |
|
| Estimated Total Program Funding: |
|
| Expected Number of Awards: |
|
| Description: |
This Funding Opportunity Announcement (FOA) supports SBIRs in the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging modalities) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic agent(s) that showed promise as evidenced by relevant, rigorous, convincing in vivo studies. Therefore, at the end of this funding period, successful projects will have delivered an optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. |
| Version: |
Synopsis 1 |
|
